WAY-267,464

WAY-267,464
(IUPAC) ime
	4-(3,5-dihydroxybenzyl)-N-(2-methyl-4-[(1-methyl-4,10-dihydropyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]benzyl)piperazine-1-carboxamide
Klinički podaci
Identifikatori
CAS broj	847375-16-0
ATC kod	nije dodeljen
PubChem	9938214
Hemijski podaci
Formula	C32H35N7O4
Mol. masa	581.663 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C32H35N7O4/c1-21-13-23(31(42)39-20-25-18-34-36(2)30(25)35-28-5-3-4-6-29(28)39)7-8-24(21)17-33-32(43)38-11-9-37(10-12-38)19-22-14-26(40)16-27(41)15-22/h3-8,13-16,18,35,40-41H,9-12,17,19-20H2,1-2H3,(H,33,43) ; Key: HWPGRFRXZNLZEX-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	?

WAY-267,464 je lek koji deluje kao nepeptidni agonist visokog afiniteta, potentnosti i selektivnosti za oksitocinski receptor, sa neznatnim afinitetom za vazopresinske receptore.^[3]^[4] Poznato je da prolazi kroz krvno-moždanu barijeru u znatno većoj meri nego oksitocin. U životinjskim ispitivivanjima proizvodi centralno-posredovano oksitocinergijsko dejstvo poput anksiolitičkih efekata, mada antidepresivno dejstvo nije evidentno.^[5]

Vidi još[uredi - уреди | uredi kôd]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Rahman Z, Resnick L, Rosenzweig-Lipson SJ, Ring RH,"Methods of treatment using oxytocin receptor agonists", US patent application 2007/0117794, published 24. 05. 2007. , assigned to Wyeth Corp
↑ Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G (2008). „Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents”. Progress in Brain Research 170: 473–512. DOI:10.1016/S0079-6123(08)00437-8. PMID 18655903.
↑ Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S (July 2009). „Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist”. Neuropharmacology 58 (1): 69–77. DOI:10.1016/j.neuropharm.2009.07.016. PMID 19615387.

	Portal Medicina
	Portal Hemija

Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).